Onbrez Brizkhaler: aktual'nye voprosy


Cite item

Full Text

Abstract

Индакатерол − новый препарат из класса длительно действующих b2-агонистов (ДДБА. Несмотря на то, что в настоящее время современные ДДБА наряду с длительно действующими антихолинергическими препаратами (ДДАХП) рассматриваются как препараты первой линии терапии больных хронической обструктивной болезнью легких (ХОБЛ), все еще ощущается потребность в дальнейшем усовершенствовании этих препаратов, так как многие пациенты с ХОБЛ не достигают оптимального контроля над заболеванием.

About the authors

S. N Avdeev

ФГУ НИИ пульмонологии ФМБА России, Москва

References

  1. Beeh K.M., Beier J. Indacaterol: a new once daily long - acting beta2 - adrenoceptor agonist. Core Evidence 2009; 4: 37–41.
  2. Moen M.D. Indacaterol in chronic obstructive pulmonary disease. Drugs 2010; 70: 2269–80.
  3. Brienza N.S., Amor-Carro Ó, Ramos-Barbón D. An update on the use of indacaterol in patients with COPD. Ther Adv Respir Dis 2011; 5: 29–40.
  4. Yorgancioglu A. Indacaterol in chronic obstructive pulmonary disease. An update for clinicians. Ther Adv Chronic Dis 2012; 3: 25–36.
  5. GOLD Guidelines. COPD Diagnosis and Management. Global Initiative for Chronic Obstructive Pulmonary Disease (2011). Available from: http://www.goldcopd.com.
  6. Cazzola M, Calzetta L, Matera M.G. b2 - adrenoceptor agonists: current and future direction. Br J Pharmacol 2011; 163: 4–17.
  7. Cazzola M, Matera M.G., Lotvall J. Ultra long - acting beta2 - agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775–83.
  8. EMEA European Medicines Agency. Evaluation of Medicines for Human Use. Assessment Report EMA/659981/2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_Public_assessment_report/human/001114/ WC500053735.pdf. Accessed: March 21, 2012.
  9. Battram C, Charlton S.J., Cuenoud B et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quino lin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762–70.
  10. Lombardi D, Cuenoud B, Kramer S.D. et al. Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties? Eur J Pharm Sci 2009; 38: 533–47.
  11. Cazzola M, Calzetta L, Matera M.G. Novel long - acting bronchodilators for COPD and asthma. Br J Pharmacol 2008; 155: 291–9.
  12. Pontier J, Percherancier Y, Galandrin S et al. Cholestero l -dependent separation of the b2 - adrenergic receptor from its partners determines signaling efficacy. Insight into nanoscale organization of signal transduction. J Biol Chem 2008; 283: 24659–72.
  13. Cazzola M, Proietto A, Matera M.G. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 2010; 46: 139–50.
  14. Roig J, Hernando R, Mora R. Indacaterol, a novel once daily inhaled b2 - adrenoreceptor agonist. Open Respir Med J 2009; 3: 27–30.
  15. Tashkin D.P., Cooper C.B. The role of long - acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249–59.
  16. Vogelmeier C, Kardos P, Harari S et al. Formoterol mono - and combination therapy with tiotropium in patients with COPD: A 6-month study. Respiry Mede 2008; 102: 1511–20.
  17. van Noord J.A., Aumann J.L., Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
  18. Чучалин А.Г., Овчаренко С.И., Авдеев С.Н. и др. Место препарата Онбрез Бризхалер (индакатерол) в терапии хронической обструктивной болезни легких: заключение экспертного совета. Пульмонология. 2011; 6: 124–5.
  19. Dahl R. Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use. European Respiratory Society (ERS) Annual Congress 2011. Abstract No. P861.
  20. Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150 mg once - daily in COPD: a doubl e -blind, randomised, 12 - week study. BMC Pulm Med 2010; 10: 11.
  21. Donohue J.F., Fogarty C, Lotvall J et al. Once - daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155–62.
  22. Kornmann O, Dahl R, Centanni S et al. Once - daily indacaterol vs twice - daily salmeterol for COPD: a placebo - controlled comparison. Eur Respir J 2011; 37: 273–9.
  23. Dahl R, Chung K.F., Buhl R et al. Efficacy of a new once daily long - acting inhaled b2 - agonist indacaterol versus twice - daily formoterol in COPD. Thorax 2010; 65: 473–9.
  24. Chapman K.R., Rennard S.I., Dogra A et al. Long - term safety and efficacy of indacaterol, a novel long - acting b2 - agonist, in subjects with COPD: a randomized, placebo - controlled study. Chest 2011; 140: 68–75.
  25. Korn S, Kerwin E, Atis S et al. Indacaterol once - daily provides superior efficacy to salmeterol twice - daily in COPD: A 12 - week study. Respir Med 2011; 105: 719–26.
  26. Buhl R, Dunn L.J., Disdier C et al. on behalf of the INTENSITY study investigators. Blinded 12 - week comparison of once - daily indacaterol and tiotropium in COPD. Eur Respir J 2011; 38: 797–803.
  27. Mahler D.A., Buhl R, Owen R et al. Indacaterol provides effective bronchodilation in patients with chronic obstructive pulmonary disease irrespective of patient age (<65 or ≥65 years) [abstract no. F93]. Am J Respir Crit Care Med 2010; 181: A4456.
  28. Donohue J.F., Decramer M, Owen R et al. Indacaterol provides significant bronchodilation in patients with chronic obstructive pulmonary disease irrespective of concomitant inhaled corticosteroid use [abstract no. F75]. Am J Respir Crit Care Med 2010; 181: A4438.
  29. Kleerup E.C., D’Urzo A, Owen R et al. Once - daily indacaterol provides significant bronchodilation in chronic obstructive pulmonary disease patients irrespective of baseline reversibility [abstract no. F76]. Am J Respir Crit Care Med 2010; 181: A4439.
  30. O’Donnell, Casaburi R, Vincken W et al. Effect of Indacaterol on exercise endu - rance and lung hyperinflation in COPD. Respir Med 2011; 105: 1030–6.
  31. Donaldson G.C., Wedzicha J.A. COPD exacerbations: epidemiology. Thorax 2006; 61: 164–8.
  32. Siler T.M., Williams J, Yegen U et al. The effect of once - daily indacaterol on health - related quality of life, rescue medication use, and exacerbation rates in patients with moderate - to - severe COPD: a pooled analysis of three months of treatment. Am J Respir Crit Care Med 2010; 181: A4430.
  33. Curtis J.R., Patrick D.L. The assessment of health status among patients with COPD. Eur Respir J Suppl 2003; 41: 36s–45s.
  34. Jones P.W., Brusselle G, Dal Negro R.W. et al. Health - related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011; 105: 57–66.
  35. Lipworth B.J. Antagonism of long - acting β-adrenoreceptor agonism. Br J Clin Pharmacol 2002; 54: 231–45.
  36. Naline E, Trifilieff A, Fairhurst R.A. et al. Effect of indacaterol, a novel long - acting b2 - agonist, on isolated human bronchi. Eur Respir J 2007; 29: 575–81.
  37. Decramer M, Donohue J, Owen R et al. Indacaterol provides effective bronchodilation in patients with COPD regardless of concomitant ICS use. European Respiratory Society (ERS) Annual Congress 2010. Abstract No. P5555.
  38. Mahler D.A., D’Urzo A, Peckitt C et al. Combining once - daily bronchodilators in COPD: Indacaterol plus tiotropium versus tiotropium alone. Presented at American Thoracic Society (ATS) International Conference, Denver Colorado, May 2011. Am J Respir Crit Care Med 2011; 183: A1591.
  39. Sears M.R. Adverse effects of beta - agonists. J Allergy Clin Immunol 2002; 110: S322–S328.
  40. Worth H, Chung K.F., Felser J.M. et al. Cardio - and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105: 571–9.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies